Defining Progression in Metastatic Kidney Cancer
3 Visninger
• 06/26/23
0
0
Indlejre
administrator
Abonnenter
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
Vis mere
Facebook kommentarer
SORT BY-
Topkommentarer
-
Seneste kommentarer